Meet Thomas Andersson, our new Senior Advisor Business Development. How could he be of help to your start-up company?
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 345 entries.
Entries by oslocancer
What does the Nobel Prize have to do with cancer research in Oslo Cancer Cluster?
Vaccibody is entering into a clinical collaboration with the American biopharmaceutical company Nektar Therapeutics.
What do you get when you combine country scale population data with world class computer systems and algorithms?
The strong life science actors in Norway joined forces during Nordic Life Science Days 2018.
What is driving the next wave of innovation in cancer immunotherapy?
Ultimovacs acquires the immunotherapy technology business of the Swedish company Immuneed AB.
PCI Biotech is initiating a scientific collaboration with Bavarian Nordic to boost their cancer treatment technology. Oslo Cancer Cluster member PCI Biotech has announced that it is initiating a preclinical research collaboration with Bavarian Nordic, a clinical stage biopharmaceutical corporation focused on developing state-of-the-art cancer immunotherapies and vaccines for infectious diseases. The two collaborators will […]
CEO of Ultimovacs Øyvind Kongstun Arnesen is the new chairman of Oslo Cancer Cluster. Get to know the guy!
Are you and your cluster company in need of early stage funding?
Can Norway take a leading international position within health industry? See the discussion from Arendalsuka.
Kan digitale løsninger lette hverdagen for pasienter som kommer hjem etter endt behandling?
Gikk du glipp av frokostmøtet vårt i Arendal? Her kan du få det med deg likevel!
MetAction has used targeted gene therapy to give patients with metastatic cancer a treatment method.
Will the Norwegian health industry become a so-called growth industry? Read the new report.
In mid-August Oslo Cancer Cluster travel to Arendal to put focus on cancer treatment and innovation. Arendalsuka is a week of political discourse and interaction, and Oslo Cancer Cluster want to highlight several cancer related topics we find important. In total, we are hosting or co-hosting three different events! On Wednesday August the 15th we […]
Aksel Stien graduated from Ullern Secondary School in 2011. Today he is a physician working on his specialty subjects at Oslo University Hospital. Aksel has always wanted to become a physician and the foundation was already in place at Ullern. He learned things from his deployment at The Norwegian Radium Hospital during his upper secondary […]
A full house presented itself when Inven2 pitched 8 of their most promising cancer research projects at Oslo Cancer Cluster Incubator June 12th. In total approximately 60 people gathered inside Oslo Cancer Cluster Innovation Park, and among the participants several experienced investors from other cancer projects. — I’m positively surprised that so many potential and […]
Øyvind Kongstun Arnesen is appointed new chairman at Oslo Cancer Cluster (OCC). On a recent General Assembly, Oslo Cancer Cluster elected Øyvind Kongstun Arnesen as new chairman after a unanimous vote. He takes over after Henrik Lund who opted not to stand for re-election after four years in the position. Øyvind is currently CEO at […]
Oslo Cancer Cluster member Immunitrack has landed investments worth millions. The money will be used to develop a computer program that can predict how the immune system will react to different substances. Already Immunitrack, co-founded by Stephan Thorgrimsen and Sune Justesen, is offering contracted research to the pharmaceutical industry predicting how the immune system react […]
Er du investor eller gründerspire? Vi trenger deg! Norge har en sterk tradisjon innen kreftforskning i verdensklasse. Basert på denne fremragende forskningen har selskaper som Algeta, Nordic Nanovector, Ultimovacs og Zelluna Immunotherapy blitt spunnet ut. Og det kommer mer. Inven2 inviterer investorer, gründerspirer og andre interesserte til en presentasjon av de mest lovende nye prosjektene […]
What are you saying “YES” to? When you register to receive information from Oslo Cancer Cluster, or register for an event: The system requires you to provide contact information such as “name” and “e-mail address”, and in some cases “affiliation”. When you reaffirm your registration by clicking “yes” from Oslo Cancer Cluster’s newsletter: Your previously […]
Our General Manager Ketil Widerberg visited the podcast People creating the future Norway (De som bygger det nye Norge) hosted by Silvija Seres and Oslo Business Forum. Ketil and Silvija discussed important issues like: Is it possible to make cancer a chronic disease? And how do you really create medicine that is tailored for each […]
Former Ullern upper secondary school student Simone Mester is enjoying a meteoric career as a researcher. Her research is aimed at making cancer drugs more efficient by getting them to stay longer in the body. But how did she end up here, and what advice does she have for upper secondary school students who are […]
Oslo Cancer Cluster member Vaccibody is making headway with their cancer vaccine technology. Now they are ready with clinical trials involving 40 patients in Germany, the first patient is already enrolled. Neoantigens Reveals Cancer Cells Cancer is famous for its ability to deceive, appearing to the immune system as normal tissue while wreaking havoc […]
For the third year running, Menon Economics presented a report on “The Value of the Norwegian Health Industry”. The conclusion: Both the industry and exports are growing substantially. We see an increase in export income, research and innovation levels. The report was launched at “Næringslivets Hus”, the home of NHO, and gathered a full house […]
Professor Harald Stenmark is granted the European Research Council’s (ERC) Advanced Grant for his cancer research. This is the second time he receives the grant; a privilege that has only befallen two other people, professor Edvard Moser (NTNU) and professor Kenneth Hugdahl (UiB). Through the grant Stenmark’s research project “Coincidence detection of proteins and lipids […]
Gentilpasset behandling har siden begynnelsen av 2000-tallet blitt beskrevet som et av de nye, viktige våpnene som kan bekjempe kreft. Hør forsker Hege G. Russnes og professor Anne Hansen Ree, her fra Cancer Crosllinks i januar i år, fortelle om deres forskningsprosjekt MetAction, og hvordan de tar i bruk gentilpasset behandling for å gi et […]
Since 2009, The Cancer Registry of Norway has made use of health data in groundbreaking ways. They have taken the Nordic HPV vaccine program and turned it into a unique study using real world data. The project manager Mari Nygård hopes the study can inspire others to use health data in a similar ways and […]
Professor Vessela Kristensen is awarded King Olav V’s Prize for Cancer Research for her breast cancer research. A Prestigious Award The prize is one million NOK and will be presented to Kristensen by his Majesty King Harald V on behalf of the Norwegian Cancer Society, April the 16th. Kristensen is a Professor at the University […]
Kommentaren stod på trykk i Finansavisen 26.02.2018 og er skrevet av Ketil Widerberg, leder i Oslo Cancer Cluster og Nard Schreurs, direktør e-helse i IKT-Norge. Vi må snakke om hvordan vi skal forvalte våre helsedata før det er for sent. På jobb får vi betalt for det vi deler og gir av tid, kreativitet eller […]
Oslo Cancer Cluster member Photocure recently announced that the U.S. Food and Drug Administration (FDA) has accepted an expansion of the bladder cancer detection system “Cysview”. The FDA has accepted a supplemental New Drug Application (NDA) for “Cysview”. Photocure, the Norwegian company behind the drug-device system, has now been allowed to expand the system to […]
Entering 2018, Oslo Cancer Cluster welcomes four new members to the fold. Cellmover, Bryn Aarflot, Kuehne + Nagel and Mercuri Urval are our new cluster members. The Importance of Getting There Founded in 1890, Kuehne + Nagel operates from 9 locations in Norway, offering tailored logistics solutions for different industries, including for healthcare and […]
Inven2 are distributing start-up funds in Life Science! Very good news for Biotechs and cancer research companies in their early stages of development. Attention all Oslo Cancer Cluster and Incubator members. Inven2 received in late December 5 million NOK from Innovation Norway. They are now, subsequently, handing them out to Life science start-ups. Inven2 […]
For the tenth time the cancer experts gathered to share knowledge and ideas at Oslo Cancer Cluster Innovation Park. Cancer Crosslinks 2018 presented a diverse program covering themes from immuno-oncology to cachexia, to big data. Cancer research is changing rapidly. Immunotherapy and precision medicine has revolutionized cancer treatment. This year’s Cancer Crosslinks took a […]
Thursday January the 18th it’s time for the 10th Cancer Crosslinks here at Oslo Cancer Cluster Innovation Park. Hospital personnel, researchers and everybody interested get together for an update on – and to discuss – the latest within cancer research. This year’s conference will focus on Precision Treatment in cancer research with the headline: […]
To secure Norwegian pharmaceutical production, Oslo Cancer Cluster- member Curida has completed a takeover of Ås produksjonslab AS. Continued Production at Ås Curida operate in an international marketplace and here the last line of production of pharmaceuticals is mostly taken care of by specialized operators. «Ås produksjonslab» is a company rich in tradition, it […]
Les kronikken, fra 21.12. 2017 i Aftenposten, om hvordan vi bør forme våre nye sykehusbygg av Ketil Widerberg. Den nye klinikken på Radiumhospitalet må ta helsedatarevolusjonen på alvor. Radiumhospitalet ved Oslo universitetssykehus får nytt klinikkbygg. En god nyhet for kreftpasienter, som blir enda bedre hvis pasientene selv får bidra med data om egen helse. Et […]
A new exciting collaboration among two Oslo Cancer Cluster members has been initiated. GE Healthcare has agreed to be the manufacturer of the target drug delivery platform ACT, made by Phoenix Solutions. Early Christmas Present As an early Christmas present to each other the two companies announced that they had signed an agreement securing manufacturing […]
The cancer research company and Oslo Cancer Cluster-member Oncoinvent opened this Thursday a brand-new lab and research facilities at Nydalen Oslo. Now they control the whole production line and continue their development of their lead product candidate Radspherin. A Good Year 2017 has been a good year for Oncoinvent. The company has now relocated and […]
Nacamed, Phoenix Soulutions, NorGenoTech and Clever Health are awarded Innovasjonsrammen for good early-stage innovation and collaboration. Innovasjonsrammen is awarded by Oslo Cancer Cluster with money from Innovation Norway. Congratulations! Important with early financing Early financing while companies are establishing their business is often limited, but can be crucial to get important projects off the ground. […]
You have probably heard of Black Friday. Now introducing Giving Tuesday: A day all about giving rather than buying. Eight Norwegian YouTubers have chosen to crowdfund on behalf of The Norwegian Cancer Society as part of Giving Tuesday. Raising money for cancer research and cancer patient care. A week before the big day five of […]
Nordic Mentor Network for Entrepreneurship (NOME) will be an important piece of the puzzle if Norway is going to fulfill their ambitions set by the coming White Paper on the Healthcare Industry. If we are to make our bioindustry more competitive and take a leading European role within eHealth, we need to learn from the […]
Researchers at the Centre for Cancer Biomedicine, a Center of Excellence and a member of Oslo Cancer Cluster, have discovered an enzyme wreaking havoc inside cells that turns into tumors. For our body to work as normal, cells need to know which way is up. When cells lose track of their orientation, they can start […]
This week on Monday, Prostate Cancer Day, the Norwegian Cancer Society initiated their Blue-Ribbon Campaign to raise prostate cancer awareness. In line with the campaign, Oslo Cancer Cluster gives you the chance to update yourselves on prostate cancer research Thursday the 30th of November. The Blue-Ribbon campaign is initially a month’s focus on prostate […]
Investors are recognizing the huge potential of Oslo Cancer Cluster member Ultimovacs. They are currently investing an additional 125 million NOK in the cancer research company. Well known investors and Ultimovacs backers Stein Erik Hagen, Anders Wilhelmsen og Bjørn Rune Gjelsten are among financiers putting fresh money into the cancer research company, according to […]
Oslo Cancer Cluster member Photucure recently announced that the U.S. Food and Drug Administration (FDA) has accepted a Priority Review for an expansion of Cysview. The FDA has accepted a supplemental New Drug Application (NDA) for Cysview on a priority review basis. Photocure, the Oslo, Norway-based company that developed and is marketing the drug-device […]
I kursserien Kompetanseutvikling i realfag (KUR), spør vi denne gangen: Er det farlig med stråling? Hvordan påvirkes vi av trådløse nettverk? Hvordan behandler man kreft med ioniserende stråling? Stråling er en del av hverdagen vår på mange måter. Det elektromagnetiske spekteret er også en gjenganger i mange læreplaner, både grunnskolen og i videregående skole. Denne kurskvelden har […]
Targovax has received very positive results regarding the survival rate of patients with pancreas cancer.
Les kronikken om digital helse av Ketil Widerberg.
Curida has come a long way from defending their place at the Norwegian factory to setting their sights internationally.
Luckily, all our events are available for a rerun.
The innovation company of the year wants to encourage young talents.
A new Norwegian research collaboration helps uncover what treatments are the right fit for American cancer patients.
Stanford programme SPARK for startup companies is coming to Norway. What exactly is SPARK?
Photocure reveals promising results in bladder cancer through the use of Blue Light Cytoscopy alongside the drug Hexvix.
On the 15th of August, drug Kadycla (trastuzumab emtansin) is finally approved by the Beslutningsforum and ready to help hundreds with breast cancer in Norway. The drug, developed by company Roche, specifically targets patients with the variant HER2 positive breast cancer – a breast cancer that tests positive for human epidermal growth factor receptor 2, […]
We are proud to introduce Oslo Cancer Cluster’s new members so far in 2017. Part 2 of 2.
We are proud to introduce Oslo Cancer Cluster’s new members so far in 2017. Part 1 of 2.
The Research Council of Norway has given Thermo Fisher Scientific the prestigious Innovation Award.
Hva har persontilpasset medisin potensial til å være – og hva skal til for å oppnå resultater av forskning og klinisk bruk? Se vårt første åpne møte under Arendalsuka 2017.
Dr. Bora Sieng, from Arctic Pharma, advocates for the importance of chemistry and encourages pupils to pursue a career in the exciting field of chemistry.
What kind of work does it take to receive PERMIDES funding for innovative concepts and projects?
Learn how Project DoMore! aims to better cancer treatment through modernized thinking and technological solutions.
The Department of Cellular Therapy is great at transforming cancer research into new companies.
24 oncology innovators from 9 international hubs attended the 6th International Cancer Cluster Showcase in San Diego.
Oslo Cancer Cluster aims to enhance the visibility of oncology innovation made in Norway. Find out how we go about making this happen.
Meet our newest board members!
Doctors, researchers and audience gather at breakfast to learn about genetics, data and how working together will help beat cancer.
A driving force behind the collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster is stepping down. This is her adventure.
The cluster-to-cluster project PERMIDES stimulates collaboration between biotech companies and IT companies. Join the workshop in Oslo 24 May.
Oslo Cancer Cluster Incubator stakk av med Siva-prisen for 2017 på årets Siva-konferanse i Trondheim.
Thermo Fisher Scientific is one of three finalists to win the award and title in Oslo this Tuesday. The technology which the biotech company is nominated for, is development of faster and cheaper DNA-sequencing. More than 70 companies were candidates for this year’s price, according to the Norwegian online tech magazine Teknisk Ukeblad. Thermo Fisher Scientific is one […]
En ny rapport om helsenæringens verdi er ute. Du kan laste ned rapporten her.
Oslo Cancer Cluster member Roche has received approval by the Norwegian Medicines Agency for a medication against a specific form for lung cancer.
Join six pupils from Ullern Upper Secondary School to see how physics plays a crucial role in good cancer treatment.
The bioinformatics company OncoImmunity AS was ranked fourth out of 250 applicants for this prestigious grant.
Oslo Cancer Cluster member Vaccibody is moving forward with the first vaccination of a patient with the HPV-virus in a IIa study using the company´s immunotherapy.
Why join the PERMIDES platform? It is where you can find your biopharma-IT match.
Åtte elever fra Ullern videregående skole har denne uken vært på utplassering hos avdeling for patologi ved Oslo universitetssykehus. Morsomt har det vært, og Marie Wahlstrøm kan godt tenke seg å bli patolog.
Targovax ASA’s shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. Targovax is a clinical stage company, developing immuno-oncology therapies to target treatment-resistant solid tumors.
The first call for proposals for the PERMIDES project is opening on March 15th. We urge all small and medium sized biopharma-companies working to take the step into the digital era: Apply for funding up to 60 000 Euros.
Nordic Mentor Network for Entrepreneurship (NOME) is an elite Nordic mentoring program for promising life science projects and startups with world class mentors.
Oslo Cancer Cluster member BerGenBio enters collaboration with MSD focused on clinical evaluation of BGB324 in combination with KEYTRUDA® (pembrolizumab) in advanced lung and breast cancer.
We are currently looking for an EU advisor with skills and experience in writing EU funding proposals. This is a fixed term contract with duration to the end of 2018.
IRW Consulting, Eisai and Personalis, Inc. are all new members of the Oslo Cancer Cluster. Please read more about them here.
De nordiske landene bør samarbeide mer for å utvikle bedre kreftbehandlinger. Sammen kan Norden bli et globalt forsknings- og testsenter for nye kreftbehandlinger og -medisiner. Det kan gi store gevinster for kreftpasienter i hele verden. Denne kronikken sto på trykk i Aftenposten torsdag 9. mars. Ketil Widerberg, daglig leder i Oslo Cancer Cluster, skrev kronikken samme uke som The Economist, Forskningsrådet og […]
Oslo, Norway, 6 March 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:
– 10th European Life Science CEO Forum
– Redeye – Fight Cancer Seminar
– 11th Annual BIO-Equity Spring 2017 Conference
Oslo Cancer Cluster has a new Head of Communications. She wants to help you reach out.
Oslo Cancer Cluster member Radium Hospital Research Foundation, Radforsk, has launched their own podcast. The podcast is named Radium, and is about cancer research and development of new cancer treatments, as well as updates on Radforsk´s portfolio companies.
Oslo, Norway, 16 February 2017 – Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results.
A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).
Are you a startup or entrepreneur in Healthcare or Life-Sciences? If yes – keep reading!
Oslo Cancer Cluster member Photocure ASA reported that full year 2016 revenues ended at NOK 143.6 million (134.7). Photocure targets revenues from the US operations to quadruple to a range of USD 15 million by 2020.
Cancer Crosslinks is now one of the most relevant meetings for Norwegian oncologists, with 300 delegates attending this year. You may download the presentations here.
Oslo Cancer Cluster is proud to be partner of the Economist Events War On Cancer Nordics. The event will gather leaders in oncology from the Nordic region and beyond, to discuss the region’s primary challenges in cancer care and control.
Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis.
The Norwegian Research Council recently granted funding to Oslo Cancer Cluster members; BerGen Bio, Bionor Immuno, GE Healthcare, Lytix Biopharma, PCI Biotech and Phoenix Solutions.
Oslo Cancer Cluster member Targovax will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017.
Lytix Biopharma, a clinical-stage biopharmaceutical company developing novel cancer immune therapies, has been awarded a NOK 15.9 million grant from The Norwegian Research Council (User-driven Research-based Innovation) to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC).
Survival rate of 68% from first patient cohort vs published historical rate of 30-53% suggests signal of clinical efficacy for the drug candidate. Full data set from first patient cohort to be submitted for presentation at ASCO annual meeting in June.
Contact Team >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.